

Biff F Palmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5899842/publications.pdf>

Version: 2024-02-01

135
papers

6,794
citations

61984

43
h-index

66911

78
g-index

135
all docs

135
docs citations

135
times ranked

7560
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebral Salt Wasting Is a Real Cause of Hyponatremia: COMMENTARY. <i>Kidney360</i> , 2023, 4, e445-e447.	2.1	3
2	Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 467-472.	4.5	12
3	Extrarenal Effects of Aldosterone on Potassium Homeostasis. <i>Kidney360</i> , 2022, 3, 561-568.	2.1	12
4	Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clinic Proceedings</i> , 2022, 97, 761-776.	3.0	13
5	Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors. <i>American Journal of Kidney Diseases</i> , 2022, 80, 158-160.	1.9	2
6	Clinical Management of Hyperkalemia. <i>Mayo Clinic Proceedings</i> , 2021, 96, 744-762.	3.0	87
7	Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1284-1291.	4.5	42
8	Amenorrhea and Estrogen Disorders in Kidney Disease. <i>Seminars in Nephrology</i> , 2021, 41, 126-132.	1.6	1
9	Sex matters: COVID-19 in kidney transplantation. <i>Kidney International</i> , 2021, 99, 555-558.	5.2	6
10	Starvation Ketosis and the Kidney. <i>American Journal of Nephrology</i> , 2021, 52, 467-478.	3.1	31
11	Renal Tubular Acidosis and Management Strategies: A Narrative Review. <i>Advances in Therapy</i> , 2021, 38, 949-968.	2.9	31
12	Potassium Binders for Hyperkalemia in Chronic Kidney Disease—Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. <i>Mayo Clinic Proceedings</i> , 2020, 95, 339-354.	3.0	64
13	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	5.2	260
14	Potassium Metabolism in Chronic Kidney Disease. , 2020, , 643-659.		0
15	Potassium binding for conservative and preservative management of chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 29-38.	2.0	5
16	Fluid overload as a therapeutic target for the preservative management of chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 22-28.	2.0	9
17	The role of estrogens in the adipose tissue milieu. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 127-143.	3.8	39
18	Potassium Homeostasis, Chronic Kidney Disease, and the Plant-Enriched Diets. <i>Kidney360</i> , 2020, 1, 65-71.	2.1	16

#	ARTICLE	IF	CITATIONS
19	The authors reply. <i>Kidney International</i> , 2020, 98, 785.	5.2	0
20	Gastrointestinal potassium binding in hemodialysis. <i>Kidney International</i> , 2020, 98, 1095-1097.	5.2	5
21	Blood pressure lowering and potassium intake. <i>Journal of Human Hypertension</i> , 2020, 34, 671-672.	2.2	10
22	Salicylate Toxicity. <i>New England Journal of Medicine</i> , 2020, 382, 2544-2555.	27.0	38
23	Let Them Eat Healthy: Can Emerging Potassium Binders Help Overcome Dietary Potassium Restrictions in Chronic Kidney Disease?. , 2020, 30, 475-483.		23
24	A Universally Accepted Definition of Gender Will Positively Impact Societal Understanding, Acceptance, and Appropriateness of Health Care. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2235-2243.	3.0	3
25	Hyperchloremic normal gap metabolic acidosis. <i>Minerva Endocrinologica</i> , 2020, 44, 363-377.	1.8	5
26	Determinants of body fat distribution in humans may provide insight about obesity-related health risks. <i>Journal of Lipid Research</i> , 2019, 60, 1710-1719.	4.2	132
27	Physiology and Pathophysiology of Potassium Homeostasis: Core Curriculum 2019. <i>American Journal of Kidney Diseases</i> , 2019, 74, 682-695.	1.9	120
28	Cardiovascular Benefits of a Diet Enriched in Fruits and Vegetables. <i>American Journal of Nephrology</i> , 2019, 49, 435-437.	3.1	4
29	Strategies to Counter Weight Loss-Induced Reductions in Metabolic Rate. <i>Current Sports Medicine Reports</i> , 2019, 18, 258-265.	1.2	4
30	The Use of Selected Urine Chemistries in the Diagnosis of Kidney Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 306-316.	4.5	34
31	Altered Prostaglandin Signaling as a Cause of Thiazide-Induced Hyponatremia. <i>American Journal of Kidney Diseases</i> , 2018, 71, 769-771.	1.9	7
32	Renal Considerations in the Treatment of Hypertension. <i>American Journal of Hypertension</i> , 2018, 31, 394-401.	2.0	9
33	Electrolyte Disturbances in Chronic Alcohol-Use Disorder. <i>New England Journal of Medicine</i> , 2018, 378, 202-204.	27.0	5
34	Do estrogens enhance activation of brown and beigeing of adipose tissues?. <i>Physiology and Behavior</i> , 2018, 187, 24-31.	2.1	31
35	Hyperkalemia across the Continuum of Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 155-157.	4.5	36
36	Activation of estrogen receptor alpha induces beigeing of adipocytes. <i>Molecular Metabolism</i> , 2018, 18, 51-59.	6.5	49

#	ARTICLE	IF	CITATIONS
37	Impact of estrogens and estrogen receptor- β in brain lipid metabolism. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E7-E14.	3.5	30
38	Sex and media: Considerations for cell culture studies. ALTEX: Alternatives To Animal Experimentation, 2018, 35, 435-440.	1.5	21
39	Thiazide-Associated Hyponatremia: A Major Dilemma Affecting Treatment. American Journal of Nephrology, 2017, 45, 417-419.	3.1	100
40	Non-shivering thermogenesis as a mechanism to facilitate sustainable weight loss. Obesity Reviews, 2017, 18, 819-831.	6.5	54
41	The effects of oestrogens and their receptors on cardiometabolic health. Nature Reviews Endocrinology, 2017, 13, 352-364.	9.6	122
42	Electrolyte Disturbances in Patients with Chronic Alcohol-Use Disorder. New England Journal of Medicine, 2017, 377, 1368-1377.	27.0	71
43	Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. Journal of the American Society of Hypertension, 2017, 11, 783-800.	2.3	81
44	Treatment of Abnormalities of Potassium Homeostasis in CKD. Advances in Chronic Kidney Disease, 2017, 24, 319-324.	1.4	10
45	Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension. American Journal of Kidney Diseases, 2017, 70, 844-858.	1.9	53
46	Challenges in Treating Cardiovascular Disease: Restricting Sodium and Managing Hyperkalemia. Mayo Clinic Proceedings, 2017, 92, 1248-1260.	3.0	8
47	Sex, Gender, and Transgender: Metabolic Impact of Cross Hormone Therapy. Advances in Experimental Medicine and Biology, 2017, 1043, 611-627.	1.6	2
48	New options for the management of chronic hyperkalemia. Kidney International Supplements, 2017, 7, 164-170.	14.2	19
49	Gonadal dysfunction in chronic kidney disease. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 117-130.	5.7	65
50	Dialysate Composition. , 2017, , 152-161.e1.		2
51	Hyponatremia in the Cancer Patient. Journal of Onco-Nephrology, 2017, 1, 87-94.	0.6	3
52	Diagnosis and treatment of hyperkalemia. Cleveland Clinic Journal of Medicine, 2017, 84, 934-942.	1.3	68
53	Physiology and pathophysiology of potassium homeostasis. American Journal of Physiology - Advances in Physiology Education, 2016, 40, 480-490.	1.6	153
54	Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. American Journal of Medicine, 2016, 129, 858-865.	1.5	35

#	ARTICLE	IF	CITATIONS
55	Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1162-1166.	2.3	28
56	Sex and Gender: Critical Variables in Pre-Clinical and Clinical Medical Research. <i>Cell Metabolism</i> , 2016, 24, 203-209.	16.2	34
57	Achieving the Benefits of a High-Potassium, Paleolithic Diet, Without the Toxicity. <i>Mayo Clinic Proceedings</i> , 2016, 91, 496-508.	3.0	79
58	A sexually dimorphic hypothalamic response to chronic high-fat diet consumption. <i>International Journal of Obesity</i> , 2016, 40, 206-209.	3.4	59
59	Hyperkalemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2405.	7.4	15
60	Regulation of Potassium Homeostasis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1050-1060.	4.5	351
61	Vasopressin Receptor Antagonists. <i>Current Hypertension Reports</i> , 2015, 17, 510.	3.5	15
62	The sexual dimorphism of obesity. <i>Molecular and Cellular Endocrinology</i> , 2015, 402, 113-119.	3.2	609
63	Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2015, 373, 548-559.	27.0	154
64	Maternal high-fat diet is associated with impaired fetal lung development. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L360-L368.	2.9	44
65	An Emerging Role of Natriuretic Peptides. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1666-1678.	3.0	16
66	Activation of natriuretic peptides and the sympathetic nervous system following Roux-en-Y gastric bypass is associated with gonadal adipose tissues browning. <i>Molecular Metabolism</i> , 2015, 4, 427-436.	6.5	60
67	Potassium Metabolism in Chronic Kidney Disease. , 2015, , 381-390.		1
68	Hypothalamic PGC-1 β Protects Against High-Fat Diet Exposure by Regulating ER α . <i>Cell Reports</i> , 2014, 9, 633-645.	6.4	159
69	Ascent to altitude as a weight loss method: The good and bad of hypoxia inducible factor activation. <i>Obesity</i> , 2014, 22, 311-317.	3.0	59
70	Oxygen sensing and metabolic homeostasis. <i>Molecular and Cellular Endocrinology</i> , 2014, 397, 51-58.	3.2	89
71	ER α upregulates Phd3 to ameliorate HIF-1 induced fibrosis and inflammation in adipose tissue. <i>Molecular Metabolism</i> , 2014, 3, 642-651.	6.5	39
72	American Society of Nephrology Quiz and Questionnaire 2013. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1132-1137.	4.5	4

#	ARTICLE	IF	CITATIONS
73	Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 11-23.	1.4	50
74	Pathophysiology of Sodium Retention and Wastage. , 2013, , 1283-1317.		2
75	American Society of Nephrology Quiz and Questionnaire 2012: Electrolytes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1048-1053.	4.5	1
76	The Role of V2 Receptor Antagonists in the Treatment of Hyponatremia. <i>Electrolyte and Blood Pressure</i> , 2013, 11, 1.	1.8	12
77	Nephrology Quiz and Questionnaire: Electrolytes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1047-1052.	4.5	0
78	Evaluation and Treatment of Respiratory Alkalosis. <i>American Journal of Kidney Diseases</i> , 2012, 60, 834-838.	1.9	30
79	Hyperkalemia in Predialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1201-1202.	4.5	11
80	Respiratory acidâ€base disorders. , 2012, , 605-611.		0
81	Metabolic Complications Associated With Use of Diuretics. <i>Seminars in Nephrology</i> , 2011, 31, 542-552.	1.6	62
82	Why are some dialysis patients chronically hypotensive in the absence of heart disease and volume depletion?. <i>Seminars in Dialysis</i> , 2011, 24, 404-405.	1.3	4
83	Screening Tests for Renal Impairment in Patients with Type 2 Diabetes: The what, when, and how. <i>Postgraduate Medicine</i> , 2011, 123, 7-14.	2.0	0
84	Physiology and Pathophysiology With Ascent to Altitude. <i>American Journal of the Medical Sciences</i> , 2010, 340, 69-77.	1.1	46
85	Diagnostic approach and management of inpatient hyponatremia. <i>Journal of Hospital Medicine</i> , 2010, 5, S1-7.	1.4	7
86	New horizons in the pharmacologic approach to hyponatremia: The V2 receptor antagonists. <i>Journal of Hospital Medicine</i> , 2010, 5, S27-S32.	1.4	2
87	A Physiologic-Based Approach to the Evaluation of a Patient With Hyperkalemia. <i>American Journal of Kidney Diseases</i> , 2010, 56, 387-393.	1.9	52
88	A Physiologic-Based Approach to the Evaluation of a Patient With Hypokalemia. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1184-1190.	1.9	52
89	Management of sexual dysfunction in uremic patients. <i>Dialysis and Transplantation</i> , 2010, 39, 370-372.	0.2	0
90	Optimizing Blood Pressure Control in Patients with Chronic Kidney Disease. <i>Baylor University Medical Center Proceedings</i> , 2010, 23, 239-245.	0.5	13

#	ARTICLE	IF	CITATIONS
91	Normal Acid-Base Balance. , 2010, , 149-154.		4
92	Metabolic Acidosis. , 2010, , 155-166.		10
93	Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. Journal of Human Hypertension, 2010, 24, 483-491.	2.2	7
94	Nephrology Quiz and Questionnaire. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1141-1160.	4.5	6
95	Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan. Current Medical Research and Opinion, 2009, 25, 2933-2949.	1.9	6
96	<i>Opinion</i>: Can Chronic Volume Overload Be Recognized and Prevented in Hemodialysis Patients?. Seminars in Dialysis, 2009, 22, 489-491.	1.3	8
97	Hyponatremia in the Intensive Care Unit. Seminars in Nephrology, 2009, 29, 257-270.	1.6	25
98	Hypertension management in patients with chronic kidney disease. Current Hypertension Reports, 2008, 10, 367-373.	3.5	9
99	Metabolic Abnormalities: Evaluation of Sexual Dysfunction. , 2008, , 930-939.		0
100	Management of Hypertension in Patients with Chronic Kidney Disease and Diabetes Mellitus. American Journal of Medicine, 2008, 121, S16-S22.	1.5	20
101	Extracellular Fluid Volume in the Hypoalbuminemic Diabetic Patient. Heart Failure Clinics, 2008, 4, 439-448.	2.1	2
102	Approach to Fluid and Electrolyte Disorders and Acid-Base Problems. Primary Care - Clinics in Office Practice, 2008, 35, 195-213.	1.6	125
103	Improving BP Control with Combined Renin-Angiotensin System Blockade and Thiazide Diuretics in Hypertensive Patients with Diabetes Mellitus or Kidney Disease. American Journal of Cardiovascular Drugs, 2008, 8, 9-14.	2.2	20
104	Supratherapeutic Doses of Angiotensin Receptor Blockers to Decrease Proteinuria in Patients with Chronic Kidney Disease. American Journal of Nephrology, 2008, 28, 381-390.	3.1	18
105	Recent Advances in the Prevention and Management of Intradialytic Hypotension. Journal of the American Society of Nephrology: JASN, 2008, 19, 8-11.	6.1	151
106	Physiology and Pathophysiology of Sodium Retention and Wastage. , 2008, , 1005-1049.		6
107	Proteinuria as a Therapeutic Target in Patients with Chronic Kidney Disease. American Journal of Nephrology, 2007, 27, 287-293.	3.1	69
108	Metabolic complications associated with use of thiazide diuretics. Journal of the American Society of Hypertension, 2007, 1, 381-392.	2.3	19

#	ARTICLE	IF	CITATIONS
109	Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension. <i>Drugs</i> , 2007, 67, 1309-1327.	10.9	86
110	Rhabdomyolysis and Acute Renal Failure Associated with Influenza Virus Type B Infection. <i>American Journal of the Medical Sciences</i> , 2006, 332, 88-89.	1.1	22
111	Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System. <i>New England Journal of Medicine</i> , 2004, 351, 585-592.	27.0	519
112	Outcomes associated with hypogonadism in men with chronic kidney disease. <i>Advances in Chronic Kidney Disease</i> , 2004, 11, 342-347.	1.4	25
113	Disturbances in Renal Autoregulation and the Susceptibility to Hypertension-Induced Chronic Kidney Disease. <i>American Journal of the Medical Sciences</i> , 2004, 328, 330-343.	1.1	43
114	Outcomes associated with hypogonadism in men with chronic kidney disease. <i>Advances in Chronic Kidney Disease</i> , 2004, 11, 342-7.	1.4	6
115	Causes and Management of Hyponatremia. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1694-1702.	1.9	125
116	Treating dyslipidemia to slow the progression of chronic renal failure. <i>American Journal of Medicine</i> , 2003, 114, 411-412.	1.5	8
117	Hyponatremia in patients with central nervous system disease: SIADH versus CSW. <i>Trends in Endocrinology and Metabolism</i> , 2003, 14, 182-187.	7.1	260
118	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1973-1975.	0.7	42
119	Sexual Dysfunction in Men and Women With Chronic Kidney Disease and End-Stage Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2003, 10, 48-60.	2.1	118
120	Renal Dysfunction Complicating the Treatment of Hypertension. <i>New England Journal of Medicine</i> , 2002, 347, 1256-1261.	27.0	286
121	Metabolic disturbances in chronic renal failure. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2002, 13, 273-80.	0.3	2
122	Impaired Renal Autoregulation: Implications for the Genesis of Hypertension and Hypertension-Induced Renal Injury. <i>American Journal of the Medical Sciences</i> , 2001, 321, 388-400.	1.1	51
123	Individualizing the Dialysate in the Hemodialysis Patient. <i>Seminars in Dialysis</i> , 2001, 14, 41-49.	1.3	33
124	Hyponatraemia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 262-268.	0.7	125
125	Pathogenesis of ascites and renal salt retention in cirrhosis. <i>Journal of Investigative Medicine</i> , 1999, 47, 183-202.	1.6	13
126	Liddle's Syndrome. <i>American Journal of Medicine</i> , 1998, 104, 301-309.	1.5	57

#	ARTICLE	IF	CITATIONS
127	Metabolic alkalosis.. Journal of the American Society of Nephrology: JASN, 1997, 8, 1462-1469.	6.1	78
128	Pathogenesis of edema formation in the nephrotic syndrome. Kidney International, Supplement, 1997, 59, S21-7.	0.1	7
129	The renal tubule in the progression of chronic renal failure. Journal of Investigative Medicine, 1997, 45, 346-61.	1.6	16
130	Systemic complications of nonsteroidal anti-inflammatory drug use. Advances in Internal Medicine, 1996, 41, 605-39.	0.9	1
131	Clinical acute renal failure with nonsteroidal anti-inflammatory drugs. Seminars in Nephrology, 1995, 15, 214-27.	1.6	36
132	Renal complications associated with use of nonsteroidal anti-inflammatory agents. Journal of Investigative Medicine, 1995, 43, 516-33.	1.6	34
133	Intravenous immunoglobulin-induced osmotic nephrosis. Archives of Internal Medicine, 1994, 154, 1985-1987.	3.8	72
134	The Effect of Dialysate Composition on Systemic Hemodynamics. Seminars in Dialysis, 1992, 5, 54-60.	1.3	14
135	Documentation of fungal pyelonephritis of the renal allograft by fine needle aspiration cytology. Transplantation Proceedings, 1989, 21, 3598-9.	0.6	6